Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preventive Administration of Lorazepam in Critically Ill Patients With High Anttila-Index to Reduce the Incidence of Intensive Care Delirium: a Single-centre, Randomized, Controlled Clinical Trial - the Basel LOC2DEL-Trial

NCT07428681 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT07428681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07428681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preventive Administration of Lorazepam in Critically Ill Patients With High Anttila-Index to Reduce the Incidence of Intensive Care Delirium: a Single-centre, Randomized, Controlled Clinical Trial - the Basel LOC2DEL-Trial
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 4
Overall status
Not yet recruiting
Start date
March 31, 2027
Completion date
February 28, 2029
Enrollment
260 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

delirium confusional state